Investment Thesis
NTHI is a pre-revenue pharmaceutical company in severe financial distress with negative stockholders' equity of -$17.5M, indicating liabilities exceed assets. The company is burning cash at an unsustainable rate (-$20.9M FCF) with minimal revenue ($40K), no clear path to profitability, and a liquidity crisis evidenced by a 0.07x current ratio with only $58.7K in cash.
Strengths
- Operates in pharmaceutical sector with potential for high-margin products if clinical programs succeed
- Minimal revenue base suggests no legacy business constraints
- Long-term debt remains modest at $320K relative to the overall capital structure problem
Risks
- Negative equity of -$17.5M creates existential solvency risk and likely insolvency
- Severe liquidity crisis with current ratio of 0.07x and only $58.7K cash against $20.3M liabilities
- Operating burn rate of -$20.4M annually is catastrophic and unsustainable without immediate capital infusion
- Revenue collapsed 51.8% YoY to only $40K, indicating complete lack of commercial traction
- Net margin of -155,404% and operating margin of -145,638% reflect fundamental business model failure
- Zero insider trading activity suggests lack of confidence from management in near-term prospects
Key Metrics to Watch
- Stockholders equity trend - critical for determining if company remains solvent
- Monthly cash burn rate and months of cash remaining
- Revenue generation and signs of clinical trial progression or partnership deals
- Capital raise announcements and dilution impact on existing shareholders
Financial Metrics
Revenue
40.0K
Net Income
-62.1M
EPS (Diluted)
$-3.20
Free Cash Flow
-20.9M
Total Assets
2.8M
Cash
58.7K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-145,637.5%
Net Margin
-155,404.4%
ROE
N/A
ROA
-2,200.9%
FCF Margin
-52,172.9%
Balance Sheet & Liquidity
Current Ratio
0.07x
Quick Ratio
0.07x
Debt/Equity
N/A
Debt/Assets
720.0%
Interest Coverage
-23.25x
Long-term Debt
320.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-03T21:20:11.282324 |
Data as of: 2025-12-31 |
Powered by Claude AI